A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects.
Phase of Trial: Phase III
Latest Information Update: 31 May 2017
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough - Merck & Co (JV)
- 18 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Feb 2014 According to the ClinicalTrials.gov record, Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 1 Feb 2016 to 1 Jun 2015.